Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as a eye drops for ocular use. It lowers intra‑ocular pressure and is used to treat open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost is a prostaglandin analogue indicated for conditions that require reduction of intra‑ocular pressure. - Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. - Ocular hypertension: reduces pressure to decrease risk of developing glaucoma. - Pseudoexfoliative glaucoma: helps control pressure in this secondary form of glaucoma.

Monoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris pigmentation: gradual brown coloration. - Ocular irritation: transient burning or stinging after instillation.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract requiring prompt evaluation. - Macular edema: fluid accumulation in the retina that can affect vision.

Before using Monoprost, consider the following precautions. - Monitor intra‑ocular pressure: assess response after initiation. - Use with caution in patients with active intra‑ocular inflammation. - Avoid in individuals with known hypersensitivity to latanoprost or excipients. - Assess risk in patients with a history of herpetic eye disease or recent ocular surgery. - Evaluate for potential cataract progression during long‑term therapy. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogues: additive IOP‑lowering effect may increase risk of side effects. - Use around ocular surgery: may impair wound healing.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce latanoprost efficacy. - Beta‑blocker eye drops: additive IOP reduction may cause excessive lowering. - Systemic carbonic anhydrase inhibitors: combined effect can lead to overly low intra‑ocular pressure.